Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Abroad (travel likely)RecruitingPHASE1

Conditions

Non Hodgkin Lymphoma · Richter Transformation · Multiple Myeloma · T-cell-prolymphocytic Leukemia · Acute Myeloid Leukemia · Acute Lymphocytic Leukemia · Myeodysplastic Syndrome · Myelodysplastic/Myeloproliferative Neoplasm · Myelofibrosis · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Chronic Myelomonocytic Leukemia-2 · Myelodysplastic Neoplasm in Blast Phase

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • University of Chicago, Chicago, Illinois, United States

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

  • University of North Carolina, Chapel Hill, North Carolina, United States

  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

  • University of Cincinnati, Cincinnati, Ohio, United States

  • The Ohio State University, Columbus, Ohio, United States

  • MD Anderson Cancer Center, Houston, Texas, United States

  • University of Utah, Salt Lake City, Utah, United States